Spark Therapeutics (ONCE) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. SPY
7. INTC
8. JBLU
9. NVDA
10. BA

Go back to Spark Therapeutics (ONCE) Misses Q3 EPS by 6c

Spark Therapeutics Reports Third Quarter 2016 Financial Results and Recent Business Highlights

November 3, 2016 8:01 AM EDT

Completion of Biologics Licensing Application (BLA) submission for investigational candidate voretigene neparvovec on track for early 2017

Company makes progress across multiple programs, including its hemophilia franchise

PHILADELPHIA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially one-time, life-altering treatments, today announced financial results for the quarter ended Sept. 30, 2016 and updated investors on its progress.

During the last few months we have continued to execute on... More